Proteo, Inc./Proteo Biotech AG: European Commission grants Orphan Drug Status to Elafin for the treatment of PAH

Dow Jones

40,589.34

Get Started

Home
Investing
Stocks
USA
USOTC
Proteo Inc (GM) (PTEO)
Proteo Inc (GM) (PTEO) News

Share Name	Share Symbol	Market	Type
Proteo Inc (GM)	USOTC:PTEO	OTCMarkets	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	179.80						0.00	01:00:00

Proteo, Inc./Proteo Biotech AG: European Commission grants Orphan Drug Status to Elafin for the treatment of PAH

29/03/2007 11:42am

Business Wire

Proteo (GM) (USOTC:PTEO)
Historical Stock Chart

From Jul 2019 to Jul 2024

Proteo, Inc. (OTCBB: PTEO; WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today: After recommendation by the European Medicines Agency (EMEA), Proteo Biotech AG has received orphan drug status from the European Commission for its drug candidate Elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. This assures the company exclusive marketing rights within the EU for a period of up to ten years after receiving approval. In addition, its designation as an orphan drug will allow access to a centralized approval procedure which will accelerate the process of approval in all EU states. Birge Bargmann, CEO of Proteo Biotech AG, >>We are confident that within a few years Elafin will be available as a new therapeutic option for the treatment of this serious disease.